Advance in Hemorrhagic Transformation after Acute Ischemic Stroke

doi:10.3969/j.issn.1673-5765.2020.04.020

Abstract

Abstract:

Hemorrhagic transformation (HT) is one of the major complications of reperfusion therapy for acute ischemic stroke (AIS), and is closely correlated with the poor prognosis of AIS. AIS treatments including intravenous thrombolysis, endovascular therapy, and antiplatelet therapy may lead to HT. Whereas there is no effective method to predict HT in AIS. This article reviewed the etiology, potential imaging markers and serum markers of HT, to provide reference for clinical prediction and treatment of HT.

Key words: Acute ischemic stroke; Hemorrhagic transformation; Serum marker; Neuroimaging marker

摘要：

出血转化是急性缺血性卒中再灌注治疗后的主要并发症之一，与缺血性卒中预后不良密切相关。急性缺血性卒中的主要治疗方案，包括阿替普酶静脉溶栓、血管内治疗及抗血小板聚集药物治疗等均可能导致出血转化。目前临床上尚无对缺血性卒中出血转化有效的预测方法，本文对缺血性卒中出血转化的病因以及影像学和生物学标志物进展进行综述，旨在为出血转化的预防和治疗提供参考。

关键词: 急性缺血性卒中; 出血转化; 血清标志物; 影像标志物

XU Ci-Hang, LI Jing-Wei, ZHU Xiao-Lei. Advance in Hemorrhagic Transformation after Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2020, 15(04): 446-451.

徐慈航，李敬伟，朱晓蕾. 急性缺血性卒中出血转化的研究进展[J]. 中国卒中杂志, 2020, 15(04): 446-451.

References

[1] YAGHI S，WILLEY J Z，CUCCHIARA B，et

al. Treatment and outcome of hemorrhagic

transformation after intravenous alteplase in acute

ischemic stroke：a scientific statement for healthcare

professionals from the American Heart Association/

American Stroke Association[J/OL]. Stroke，2017，

48（12）：e343-e361[2019-12-15]. https：//doi.

org/10.1161/STR.0000000000000152.

[2] TSIRKA S E，GUALANDRIS A，AMARAL D

G，et al. Excitotoxin-induced neuronal degeneration

and seizure are mediated by tissue plasminogen

activator[J]. Nature，1995，377（6547）：340-344.

[3] LIU D，CHENG T，GUO H，et al. tPA neurovascular

toxicity is controlled by activated protein C[J]. Nat

Med，2004，10（12）：1379-1383.

[4] CUADRADO E，ORTEGA L，HERNÁNDEZGUILLAMON

M，et al. Tissue plasminogen

activator（t-PA）promotes neutrophil degranulation

and MMP-9 release[J]. J Leukoc Biol，2008，84（1）：

207-214.

[5] LU G，HE Q，SHEN Y，et al. Potential biomarkers

for predicting hemorrhagic transformation of

ischemic stroke[J]. Int J Neurosci，2018，128（1）：

79-89.

[6] HARTMANN S，RIDLEY A J，LUTZ S. The

function of rho-associated kinases ROCK1 and

ROCK2 in the pathogenesis of cardiovascular

disease[J]. Front Pharmacol，2015，6（5）：276.

[7] JICKLING G C，LIU D，STAMOVA B，et al.

Hemorrhagic transformation after ischemic stroke in

animals and humans[J]. J Cereb Blood Flow Metab，

2014，34（2）：185-199.

[8] YAMAGUCHI T，AWANO H，MATSUDA H，et

al. Edaravone with and without. 6 mg/kg alteplase

within 4.5 hours after ischemic stroke：a prospective

cohort study（PROTECT 4.5）[J]. J Stroke

Cerebrovasc Dis，2017，26（4）：756-765.

[9] CAMPOS F，QIN T，CASTILLO J，et al. Fingolimod

reduces hemorrhagic transforma tion associated with

delayed tissue plasminogen activator treatment in a

mouse thromboembolic model[J]. Stroke，2013，44

（2）：505-511.

[10] ROGOVE A D，SIAO C，KEYT B，et al. Activation

of microglia reveals a non-proteolytic cytokine

function for tissue plasminogen activator in the

central nervous system[J]. J Cell Sci，1999，112（22）：

4007-4016.

[11] SHI Z S，DUCKWILER G R，JAHAN R，et al.

Early blood‐brain barrier disruption after mechanical

thrombectomy in acute ischemic stroke[J]. J

Neuroimaging，2018，28（3）：283-288.

[12] SHI Z S，LIEBESKIND D S，LOH Y，et al，

Predictors of subarachnoid hemorrhage in acute

ischemic stroke with endovascular therapy[J]. Stroke，

2010，41（12）：2775-2781.

[13] SAVER J L，GOYAL M，VAN DER LUGT A，et al.

Time to treatment with endovascular thrombectomy

and outcomes from ischemic stroke：a metaanalysis[

J]. JAMA，2016，316（12）：1279-1288.

[14] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，

et al. Thrombectomy 6 to 24 hours after stroke with

a mismatch between deficit and infarct[J]. N Engl J

Med，2018，378（1）：11-21.

[15] ALBERS G W，MARKS M P，KEMP S，et al.

Thrombectomy for stroke at 6 to 16 hours with

selection by perfusion imaging[J]. N Engl J Med，

2018，378（8）：708-718.

[16] International Stroke Trial Collaborative Group. The

International Stroke Trial（IST）：a randomised

trial of aspirin，subcutaneous heparin，both，or

neither among 19 435 patients with acute ischaemic

stroke[J]. Lancet，1997，349（9065）：1569-1581.

[17] TSIVGOULIS G，KATSANOS A H，MAVRIDIS D，

et al. Intravenous thrombolysis for ischemic stroke

patients on dual antiplatelets[J]. Ann Neurol，2018，

84（1）：89-97.

[18] DIEDLER J，AHMED N，SYKORA M，et al. Safety

of intravenous thrombolysis for acute ischemic

stroke in patients receiving antiplatelet therapy at

stroke onset[J]. Stroke，2010，41（2）：288-294.

[19] LUO S，ZHUANG M，ZENG W，et al. Intravenous

thrombolysis for acute ischemic stroke in patients

receiving antiplatelet therapy：a systematic review

and meta-analysis of 19 studies[J/OL]. J Am Heart

Assoc，2016，5（5）：e003242[2019-12-15]. https：//

doi.org/10.1161/JAHA.116.003242.

[20] SA?ÁK D，KULIHA M，HERZIG R，et al. Prior

use of antiplatelet therapy can be associated with

a higher chance for early recanalization of the

occluded middle cerebral artery in acute stroke

patients treated with intravenous thrombolysis[J].

Eur Neurol，2012，67（1）：52-56.

[21] ZINKSTOK S M，ROOS Y B，ARTIS investigators.

Early administration of aspirin in patients treated

with alteplase for acute ischaemic stroke：a

randomised controlled trial[J]. Lancet，2012，380

（9843）：731-737.

[22] RESTART Collaboration. Effects of antiplatelet

therapy after stroke due to intracerebral haemorrhage

（RESTART）：a randomised，open-label trial[J].

Lancet，2019，393（10 191）：2613-2623.

[23] WHITELEY W N，SLOT K B，FERNANDES P，et

a1. Risk factors for intracranial hemorrhage in acute

ischemic stroke patients treated with recombinant

tissue plasminogen activator：a systematic review

and meta-analysis of 55 studies[J]. Stroke，2012，43

（111）：2904-2909.

[24] 中华医学会神经病学分会与中华医学会神经病学分

会脑血管病学组. 中国急性脑梗死后出血转化诊治

共识2019[J]. 中华神经科杂志，2019，52（4）：252-

265.

[25] KUDO K，SASAKI M，YAMADA K，et al.

Differences in CT perfusion maps generated by

different commercial software：quantitative analysis

by using identical source data of acute stroke

patients[J]. Radiology，2010，254（1）：200-209.

[26] YASSI N，PARSONS M W，CHRISTENSEN

S，et al. Prediction of poststroke hemorrhagic

transformation using computed tomography

perfusion[J]. Stroke，2013，44（11）：3039-3043.

[27] SHI F，GONG X，LIU C，et al. Acute stroke：

prognostic value of quantitative collateral assessment

at perfusion CT[J]. Radiology，2019，290（3）：760-

768.

[28] EL NAWAR R，YEUNG J，LABREUCHE J，et al.

MRI-based predictors of hemorrhagic transformation inpatients with stroke treated by intravenous

thrombolysis[J]. Front Neurol，2019，10（6）：897.

[29] SCALZO F，ALGER J R，HU X，et a1. Multicenter

prediction of hemorrhagic transformation in

acute ischemic stroke using permeability imaging

features[J]. Magn Reson Imaging，2013，31（6）：

961-969.

[30] CAMPBELL B C，CHRISTENSEN S，BUTCHER

K S，et a1. Regional very low cerebral blood volume

predicts hemorrhagic transformation better than

diffusion-weighted imaging volume and thresholded

apparent diffusion coefficient in acute ischemic

stroke[J]. Stroke，2010，41（1）：82-88.

[31] CHARIDIMOU A，SHOAMANESH A，

International META-MICROBLEEDS Initiative.

Clinical relevance of microbleeds in acute stroke

thrombolysis[J]. Neurology，2016，87（15）：1534-

1541.

[32] TURC G，SALLEM A，MOULIN S，et al.

Microbleed status and 3-month outcome after

intravenous thrombolysis in 717 patients with acute

ischemic stroke[J]. Stroke，2015，46（9）：2458-2463.

[33] KELLY P J，MORROW J D，NING M，et al.

Oxidative stress and matrix metalloproteinase-9 in

acute ischemic stroke：the Biomarker Evaluation

for Antioxidant Therapies in Stroke（BEAT-Stroke）

study[J]. Stroke，2008，39（1）：100-104.

[34] TURNER R J，SHARP F R. Implications of MMP9

for blood brain barrier disruption and hemorrhagic

transformation following ischemic stroke[J]. Front

Cell Neurosci，2016，10（6）：56.

[35] FOERCH C，WUNDERLICH M T，DVORAK

F，et al. Elevated serum S100B levels indicate a

higher risk of hemorrhagic transformation after

thrombolytic therapy in acute stroke[J]. Stroke，2007，

38（9）：2491-2495.

[36] LUGER S，WITSCH J，DIETZ A，et al. Glial

fibrillary acidic protein serum levels distinguish

between intracerebral hemorrhage and cerebral

ischemia in the early phase of stroke[J]. Clin Chem，

2017，63（1）：377-385.

[37] MAESTRINI I，STRBIAN D，GAUTIER S，et

al. Higher neutrophil counts before thrombolysis

for cerebral ischemia predict worse outcomes[J].

Neurology，2015，85（16）：1408-1416.

[38] LEE J H，PARK K Y，SHIN J H，et al. Symptomatic

hemorrhagic transformation and its predictors in

acute ischemic stroke with atrial fibrillation[J]. Eur

Neurol，2010，64（4）：193-200.

[39] GORI A M，GIUSTI B，PICCARDI B，et al.

Inflammatory and metalloproteinases profiles predict

three-month poor outcomes in ischemic stroke

treated with thrombolysis[J]. J Cereb Blood Flow

Metab，2017，37（9）：3253-3261.

[40] KANAZAWA M，IGARASHI H，KAWAMURA

K，et al. Inhibition of VEGF signaling pathway

attenuates hemorrhage after tPA treatment[J]. J

Cereb Blood Flow Metab，2011，31（6）：1461-1474.

[41] SOBRINO T，MILLAN M，CASTELLANOS M，

et al. Association of growth factors with arterial

recanalization and clinical outcome in patients

with ischemic stroke treated with tPA[J]. J Thromb

Haemost，2010，8（7）：1567-1574.

[42] RODRIGUEZ-YANEZ M，CASTELLANOS M，

BLANCO M，et al. Micro and macroalbuminuria

predict hemorrhagic transformation in acute

ischemic stroke[J]. Neurology，2006，67（7）：1172-

1177.

[43] KASE C S，FURLAN A J，WECHSLER L R，

et al. Cerebral hemorrhage after intra-arterial

thrombolysis for ischemic stroke：the PROACT Ⅱ

trial[J]. Neurology，2001，57（9）：1603-1610.

[44] LEE J H，PARK K Y，SHIN J H，et al. Symptomatic

hemorrhagic transformation and its predictors in

acute ischemic stroke with atrial fibrillation[J]. Eur

Neurol，2010，64（4）：193-200.

[45] YANG N，LIN M，WANG B G，et al. Low level

of low-density lipoprotein cholesterol is related

with increased hemorrhagic transformation after

acute ischemic cerebral infarction[J]. Eur Rev Med

Pharmacol Sci，2016，20（4）：673-678.

[46] LIU，J，WANG D，XIONG Y，et al. Low free

triiodothyronine levels are related to symptomatic

intracranial hemorrhage and poor functional

outcomes after intravenous thrombolysis in acute

ischemic stroke patients[J]. Neurol Res，2016，38（5）：

429-433.